Lymphomatoid Papulosis

Watchlist

(log in to enable)

Retrieved

2021-01-18

Source

Wikipedia

Trials

—

Genes

NPM1, TYK2, TNFRSF8, ALK, NCAM1, ACSBG1, PDLIM7, RAPH1, TNFSF8, CCR3, SATB1, CXCR3, HLA-DQB1, PRDM8, FOXP3, SMUG1, CD8A, TOX, SOCS3, CXCR4, TIA1, PDGFRA, CCR4, FCGRT, KIT, B2M, INS, IL10, IL4, IL2

NPM1, TYK2, TNFRSF8, ALK, NCAM1, ACSBG1, PDLIM7, RAPH1, TNFSF8, CCR3, SATB1, CXCR3, HLA-DQB1, PRDM8, FOXP3, SMUG1, CD8A, TOX, SOCS3, CXCR4, TIA1, PDGFRA, CCR4, FCGRT, KIT, B2M, INS, IL10, IL4, IL2, IL1RN, IL1B, IL1A, IRF4

Drugs

A-dmDT390-bisFv(UCHT1), Adenovirus-Interferon gamma - coding DNA sequence, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Brentuximab vedotin ( ADCETRIS ), Chlormethine ( Ledaga ), Denileukin diftitox, Fenretinide, Forodesine hydrochloride, Human monoclonal antibody against CD4, Humanised IgG1 monoclonal antibody against human KIR3DL2, Iodine (131I) tositumomab, Miltefosine ( IMPAVIDO ), Mogamulizumab ( POTELIGEO ), Naloxone hydrochloride dihydrate, Panobinostat ( FARYDAK ), Pralatrexate ( FOLOTYN ), Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein, Resiquimod, Rituximab ( BLITZIMA, MABTHERA, TRUXIMA, RITEMVIA, RITUXAN, RITUZENA, RIXATHON, RIXIMYO, Ruxience ), Romidepsin ( ISTODAX ), Siplizumab, Suberolylanilide hydroxamic acid, Synthetic hypericin, Vorinostat ( ZOLINZA ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Lymphomatoid papulosis (LyP) is a rare skin disorder. The overall prevalence rate of lymphomatoid papulosis is estimated at 1.2 to 1.9 cases per 1,000,000 population. This rare condition has only been studied in depth since 1968.

Presentation

It can appear very similar to anaplastic large cell lymphoma. Type "A" is CD30 positive, while type "B" is CD30 negative.

It has been described as "clinically benign but histologically malignant."

Cause

Diagnosis

Treatment

It may respond to methotrexate or PUVA.

Prognosis